Claims for Patent: 10,206,877

Summary for Patent: 10,206,877

Title:	Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
Abstract:	The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.
Inventor(s):	Phenix; Brian Dean (Acton, MA), Bagnol; Laurent Jean-Claude (Burlington, MA), Brodeur; Geoffrey Glen (Somerville, MA), Chandran; Sachin (Somerville, MA), Dokou; Eleni (Cambridge, MA), Ferris; Lori Ann (Medford, MA), Knezic; Dragutin (Watertown, MA), McCarty; Katie Lynn (Watertown, MA), Medek; Ales (Winchester, MA), Waggener; Sara A. (N. Billerica, MA)
Assignee:	Vertex Pharmaceuticals Incorporated (Boston, MA)
Application Number:	14/686,117
Patent Claims:	1. A pharmaceutical composition comprising a blend of a first solid dispersion and a second solid dispersion, wherein the first solid dispersion comprises 70 wt % to 90 wt % of amorphous (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6- -fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarbox- amide (Compound 1) relative to the total weight of the first solid dispersion and 10 wt % to 30 wt % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion, wherein the second solid dispersion comprises 70 wt % to 90 wt % of amorphous N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline- -3-carboxamide (Compound 2) relative to the total weight of the second solid dispersion, and wherein the pharmaceutical composition is a tablet which comprises 25 mg to 125 mg of Compound 1 and 100 mg to 200 mg of Compound 2. 2. The pharmaceutical composition of claim 1, wherein the second solid dispersion further comprises 10 wt % to 30 wt % of a polymer relative to the total weight of the second solid dispersion. 3. The pharmaceutical composition of claim 2, wherein the polymer in the second solid dispersion comprises hydroxypropyl methylcellulose acetate succinate. 4. The pharmaceutical composition of claim 1, wherein the first solid dispersion comprises 80 wt % of amorphous Compound 1 relative to the total weight of the first solid dispersion and 20 wt % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion. 5. The pharmaceutical composition of claim 1, wherein the tablet comprises 100 mg of Compound 1. 6. The pharmaceutical composition of claim 1, wherein the tablet comprises 150 mg of Compound 2. 7. The pharmaceutical composition of claim 1, wherein the tablet comprises one or more excipients selected from a filler, a disintegrant, a lubricant, or any combination thereof. 8. The pharmaceutical composition of claim 7, wherein the tablet comprises a filler in an amount of 30 wt % to 50 wt % relative to the total weight of the tablet. 9. The pharmaceutical composition of claim 8, wherein the filler comprises microcrystalline cellulose. 10. The pharmaceutical composition of claim 7, wherein the tablet comprises a disintegrant in an amount of 1 wt % to 10 wt % relative to the total weight of the tablet. 11. The pharmaceutical composition of claim 10, wherein the disintegrant comprises croscarmellose sodium. 12. The pharmaceutical composition of claim 7, wherein the tablet comprises a lubricant in an amount of 1 wt % relative to the total weight of the tablet. 13. The pharmaceutical composition of claim 12, wherein the lubricant comprises magnesium stearate. 14. The pharmaceutical composition of claim 7, wherein the tablet comprises 100 mg to 300 mg of a filler. 15. The pharmaceutical composition of claim 7, wherein the tablet comprises 12 mg to 36 mg of a disintegrant. 16. The pharmaceutical composition of claim 7, wherein the tablet comprises 5.9 mg of a lubricant. 17. The pharmaceutical composition of claim 1, wherein the tablet comprises: 125 mg of a first solid dispersion which comprises 80 wt % of amorphous Compound 1 relative to the total weight of the first solid dispersion and 20 wt % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion, 187.5 mg of a second solid dispersion which comprises 80 wt % of amorphous Compound 2 relative to the total weight of the second solid dispersion, 19.5 wt % of hydroxypropyl methylcellulose acetate succinate relative to the total weight of the second solid dispersion, and 0.5 wt % of sodium lauryl sulfate relative to the total weight of the second solid dispersion, 243.9 mg microcrystalline cellulose, 29.6 mg croscarmellose sodium, and 5.9 mg magnesium stearate. 18. A method of treating cystic fibrosis in a patient comprising orally administering to the patient the pharmaceutical composition of claim 1. 19. The method of claim 18, wherein the pharmaceutical composition is administered once per day. 20. The method of claim 18, wherein the pharmaceutical composition is administered once per day followed by the administration of 150 mg of Compound 2 once per day. 21. The method of claim 18, wherein the patient is heterozygous for a .DELTA.F508 cystic fibrosis transmembrane conductance regulator (CFTR) gene mutation and a second CFTR gene mutation. 22. The method of claim 21, wherein the second CFTR gene mutation is selected from E56K, P67L, R74W, D110E, D110H, R117C, E193K, L206W, R347H, R352Q, A455E, D579G, 711+3A.fwdarw.G, S945L, S977F, F1052V, K1060T, A1067T, R1070W, F1074L, D1152H, D1270N, 2789+5G.fwdarw.A, 3272-26A.fwdarw.G, and 3849+10kbC.fwdarw.T. 23. The method of claim 21, wherein the second CFTR gene mutation is selected from R117H, G178R, S549N, S549R, G551D, G551S, G1244E, S1251N, S1255P, and G1349D. 24. The method of claim 21, wherein the second CFTR gene mutation is selected from G576A and R668C. 25. The method of claim 18, wherein the patient is homozygous for the .DELTA.F508 CFTR gene mutation. 26. A method of treating cystic fibrosis in a patient comprising orally administering to the patient a tablet comprising 125 mg of a first solid dispersion which comprises 80 wt % of amorphous Compound 1 relative to the total weight of the first solid dispersion and 20 wt % of hydroxypropyl methylcellulose relative to the total weight of the first solid dispersion, 187.5 mg of a second solid dispersion which comprises 80 wt % of amorphous Compound 2 relative to the total weight of the second solid dispersion, 19.5 wt % of hydroxypropyl methylcellulose acetate succinate relative to the total weight of the second solid dispersion, and 0.5 wt % of sodium lauryl sulfate relative to the total weight of the second solid dispersion, 22.9 mg microcrystalline cellulose, 29.6 mg croscarmellose sodium, and 5.9 mg magnesium stearate. 27. The method of claim 18, wherein the method produces an increase in chloride transport which is greater than or equal to 10% above the baseline chloride transport.